Background: There is limited information on decay of persistent viremia in patients on long-term ART with HIV-1 RNA < 50 copies(c)/mL. We evaluated patterns of persistent viremia and evidence for ongoing decay in a large cohort of patients on suppressive ART for >10 years. Methodology: Plasma samples obtained at approximately 4, 7, 10, and 12 years after ART initiation from subjects enrolled in the ACTG ALLRT cohort (A5001) were tested for HIV-1 RNA with a single copy assay (SCA) targeting HIV-1 gag. Selected subjects were ART-naive at baseline, had HIV-1 RNA <50 c/mL from week 32 of ART forward, with ≥ 3 mL of stored plasma available at each time point. SCA amplification efficiency, compared to the Roche HIV Monitor assay v1.5, was determined from pre-therapy plasma for subjects with SCA < 1 c/mL. The limit of detection of the SCA for 3 mL of plasma was 0.6 c/mL. A decline in the likelihood of HIV-1 RNA being ≥ 1 c/mL during follow-up was assessed using a repeated measures logistic regression model. Results: Plasma SCA was performed on 4 to 6 samples each from 64 subjects: two measurements were obtained at 4 years of ART (Weeks 192 and 208); and 2-4 measurements were obtained at 2-3 year intervals thereafter. Median duration from ART initiation to last SCA was 11.2 years. Subjects were categorized into 3 groups based on the results at year 4: Persistent viremia (+/+ defined as SCA ≥ 1c/mL at both Weeks 192 and 208; N=17), Intermittent viremia (+/- or -/+; SCA ≥ 1c/mL at 1 of the 2 time points; N=25), or Undetectable (-/-; <1 c/mL at both; N=22). Subject characteristics by group are shown in the Table. Pre-ART HIV-1 RNA levels differed across groups (p=0.027, Kruskal-Wallis) with highest levels in the Persistent viremia group (Table). Subjects with Persistent viremia during year 4 generally had viremia ≥ 1c/mL at years 7 and 10 (65% and 56%, respectively); by contrast, subjects with Undetectable viremia during year 4 rarely had viremia ≥ 1c/mL at years 7 and 10 (14% and 9%, respectively) (Table). In the subset with SCA ≥ 1c/mL at Week 192 (N=27 with total of 111 subsequent SCA measurements) the median SCA at Years 4, 7, and 10 was 1.9, 1.5, and 1.3 c/mL, respectively, and there was no evidence (p=0.55) of a decline in the probability of SCA ≥ 1c/mL over time. Conclusions: The level of residual viremia measured at ~4 years of suppressive ART remained stable for up to 11 years post-ART follow up with no clear evidence for further decay. The mechanisms responsible for stable persistence of different levels of viremia on ART require investigation.